MAPPING THE CONTOURS OF THE EXPERIMENTAL USE EXEMPTION: 35 U.S.C. sect. 271(E)(1)'S PAST, PRESENT, AND FUTURE

DSpace/Manakin Repository

dc.contributor.advisor	Hutt, Peter Barton	en_US
dc.contributor.author	Concannon, Sarah H.	en_US
dc.date.accessioned	2012-06-15T20:18:58Z
dc.date.issued	2000	en_US
dc.identifier.citation	MAPPING THE CONTOURS OF THE EXPERIMENTAL USE EXEMPTION: 35 U.S.C. sect. 271(E)(1)'S PAST, PRESENT, AND FUTURE (2000 Third Year Paper)	en
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:8889446
dc.description.abstract	In 1984, Congress passed the Drug Price Competition and Patent Term Restoration Act (DPCPTR). This Act, which resulted from the lobbying efforts of both the pharmaceutical industry and consumer interest groups, was intended to encourage greater expenditure in the area of pharmaceutical invention while simultaneously ensuring greater competition immediately after the expiration of the relevant patents. "By rectifying distortions in the patent system created by the Food and Drug Administration's [FDA's] regulatory approval process, Congress struck a balance between the interests of pharmaceutical companies, competing 'generic' manufacturers," and consumers.	en
dc.language.iso	en_US	en
dash.license	LAA	en_US
dc.subject	Food and Drug Law	en
dc.subject	patents	en
dc.subject	FDA	en
dc.subject	experimental	en
dc.subject	Drug Price Competition and Patent Term Restoration Act	en
dc.subject	veterinary products	en
dc.title	MAPPING THE CONTOURS OF THE EXPERIMENTAL USE EXEMPTION: 35 U.S.C. sect. 271(E)(1)'S PAST, PRESENT, AND FUTURE	en
dc.type	Paper (for course/seminar/workshop)	en_US
dc.date.available	2012-06-15T20:18:58Z

Files	Size	Format	View
Concannon,_Sarah_paper_00.pdf	253.8Kb	PDF	View/Open
Concannon,_Sarah_paper_00.rtf	180.1Kb	RTF file	View/Open
Concannon,_Sarah_paper_00.html	202bytes	HTML	View/Open